Royalty Pharma and Immunomedics’ $250 Million Royalty Funding and Stock Purchase Agreements

Ambrogio Visconti

Goodwin advised Royalty Pharma on its agreement to buy tiered, sales-based royalty rights on the global net sales of sacituzumab govitecan from Immunomedics for $175 million….

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Ambrogio Visconti

…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here